We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    02582879
Previous Study | Return to List | Next Study

informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia (informCLL)

This study is currently recruiting participants.
Verified June 2017 by Pharmacyclics LLC.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02582879
First Posted: October 21, 2015
Last Update Posted: June 22, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Collaborator:
Janssen, LP
Information provided by (Responsible Party):
Pharmacyclics LLC.
  Purpose
The purpose of the InformCLL Registry is to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL /SLL therapies/regimens. This study also evaluates association of treatment patterns with patient characteristics, healthcare resource utilization and patient reported Health related Quality of Life (HRQoL).

Condition
Chronic Lymphocytic Leukemia (CLL)

Study Type: Observational [Patient Registry]
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 2 Years
Official Title: informCLL™: A Disease Registry for Patients With Chronic Lymphocytic Leukemia

Resource links provided by NLM:


Further study details as provided by Pharmacyclics LLC.:

Primary Outcome Measures:
  • Summarize baseline characteristics of study population, among CLL patients in a real-world setting [ Time Frame: up to 5 years ]
    - Summarize baseline characteristics of study participants

  • Summarize treatment patterns among CLL patients in a real-world setting [ Time Frame: up to 5 years ]
    • Summarize number of participants on various initial and subsequent treatments
    • Summarize proportion of patients switching therapies at each follow up time point

  • Summarize clinical outcomes among CLL patients in a real-world setting [ Time Frame: up to 5 years ]
    - Measures of effectiveness used will include survival status, ECOG Health status, response assessments as evaluated by the investigator such as: complete response, partial response, stable disease, progressive disease

  • Summarize health care resource utilization among CLL patients in a real-world setting [ Time Frame: up to 5 years ]
    - Summarize health care resource utilization among study participants


Secondary Outcome Measures:
  • Summarize non serious adverse events (AEs) that led to discontinuation/modification/interruption of therapy and all serious adverse events in CLL patients [ Time Frame: up to 5 years ]
    - Summarize frequencies and percentages of AEs, that led to discontinuation/modification/interruption of therapy or death in CLL patients

  • Summarize patient-reported HRQoL scores [ Time Frame: up to 5 years ]
    - Summarize HRQoL scores as measured by FACT-G and additional questions from other PRO instruments at baseline and each follow-up


Biospecimen Retention:   Samples With DNA
blood samples

Estimated Enrollment: 1500
Study Start Date: September 2015
Estimated Study Completion Date: October 2020
Estimated Primary Completion Date: October 2020 (Final data collection date for primary outcome measure)
Groups/Cohorts
Patient with CLL/SLL
Patients with CLL/SLL in a real-world setting initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens.

Detailed Description:
InformCLL is a multicenter, prospective, observational registry of CLL patients designed to characterize and describe treatment patterns for those initiating treatment with approved oral kinase inhibitors, BCL-2 inhibitors and other approved anti-CLL therapies/regimens. The registry will provide information on regimens used to treat first-line and later lines of CLL/SLL as well as the sequencing of treatment regimens. The registry will also evaluate the association of these treatment patterns with patient characteristics, healthcare resource utilization, and functional outcomes including patient-reported HRQoL. These data will provide information to physicians that may help guide clinical practice and appropriate use of therapies, and will also provide information on HRQoL and healthcare resource utilization that will be of interest to healthcare decision makers.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with CLL/SLL from approximately 200 sites in the US over a 36-month enrollment period. Approximately 1000 patients will be initiating novel therapies including oral kinase inhibitors and approximately 500 patients initiating other approved anti-CLL therapies/regimens for the treatment of CLL/SLL. Approximately 85% of sites will include sites from the community hematology-oncology setting.
Criteria

Inclusion Criteria:

  • Age of at least 18 years
  • Clinical diagnosis of CLL/SLL that meets published diagnostic criteria (Hallek 2008)
  • Initiating treatment within ±30 days of enrollment with novel therapies including oral kinase inhibitors (e.g., inhibitors of BTK [e.g., ibrutinib],inhibitors of BCL-2 pathway [ e.g venetoclax] or PI3K [e.g., idelalisib]), or with other anti-CLL therapies/regimens approved at the time of patient enrollment
  • Availability of documentation of previous CLL/SLL treatment and duration of response in the patient's medical records
  • Willing and able to provide informed consent
  • Willing and able to complete PRO instrument
  • Willing and able to provide information on patient survey questionnaire
  • Willing and able to provide a blood sample at time of enrollment

Exclusion Criteria:

  • Diagnosis of B-cell malignancies other than CLL/SLL
  • Estimated life expectancy <6 months
  • Currently receiving treatment in an interventional clinical trial with a non-approved, investigational agent for CLL/SLL at study entry (note: patients who enroll in an interventional clinical trial after enrollment may remain in the registry)
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02582879


Contacts
Contact: Divya Chari informCLL@pcyc.com

  Show 166 Study Locations
Sponsors and Collaborators
Pharmacyclics LLC.
Janssen, LP
  More Information

Publications:
Responsible Party: Pharmacyclics LLC.
ClinicalTrials.gov Identifier: NCT02582879     History of Changes
Other Study ID Numbers: PCYC-1134 M
First Submitted: September 8, 2015
First Posted: October 21, 2015
Last Update Posted: June 22, 2017
Last Verified: June 2017

Keywords provided by Pharmacyclics LLC.:
Chronic Lymphocytic Leukemia
CLL
Small Lymphocytic Leukemia
SLL

Additional relevant MeSH terms:
Leukemia
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell